Defibrotide
- Generic Name
- Defibrotide
- Brand Names
- Defitelio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 83712-60-1
- Unique Ingredient Identifier
- 568FY5I1YI
- Background
Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a...
- Indication
Indicated for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
- Associated Conditions
- Sinusoidal Obstruction Syndrome (SOS)
- Associated Therapies
- -
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 152
- Registration Number
- NCT03339297
- Locations
- 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria
🇭🇷Klinichki Bolnicki Centar Zagreb, Zagreb, Croatia
🇩🇪Uniklinik Köln, Köln, Germany
Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide
- Conditions
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Bernd Jilma
- Target Recruit Count
- 20
- Registration Number
- NCT02876601
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 372
- Registration Number
- NCT02851407
- Locations
- 🇯🇵
Osaka City University Hospital, Osaka, Japan
🇯🇵Medical Hospital Tokyo Medical and Dental University, Tokyo, Japan
🇰🇷Severance Hospital at Yonsei University Health System, Seoul, Korea, Republic of
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 40
- Registration Number
- NCT02675959
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 1206
- Registration Number
- NCT00628498
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Maryland - Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2016-05-10
- Lead Sponsor
- Silvio Aime
- Target Recruit Count
- 24
- Registration Number
- NCT00406978
- Locations
- 🇮🇹
Div. Univ. Di Ematologia, Az. Osp. San Giovanni Battista, Torino, TO, Italy
🇮🇹Dip. Scienze Mediche & IRCAD-Università, UDA Ematologia, Novara, Italy
🇮🇹Servizio di Ematologia, Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 134
- Registration Number
- NCT00358501
Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2011-06-09
- Target Recruit Count
- 360
- Registration Number
- NCT00272948
- Locations
- 🇩🇪
Klinik Kinder-Onkologie, Düsseldorf, Germany
🇬🇧Children's Hospital, Manchester, United Kingdom
🇮🇹Institute G. Gaslini, Genova, Italy
Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver
- Conditions
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Emory University
- Registration Number
- NCT00263978
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- St. Jude Children's Research Hospital
- Registration Number
- NCT00143546
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.